Medicare proposes limiting coverage of controversial Alzheimer's drug

Jan 13, 2022
Government insurer won't cover Aduhelm's $28,000-a-year price tag except for clinical trials.
A sign for biotechnology company, Biogen, Inc. is seen on a building in Cambridge, Massachusetts.
DOMINICK REUTER/AFP via Getty Images

Who will end up paying the price for Biogen's new Alzheimer's drug?

Jun 18, 2021
The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.
Biogen’s new Alzheimer's treatment drug, Aduhelm, has an annual sticker price of $56,000.
Dominick Reuter/AFP via Getty Images